RSS

Kevzara

Sanofi and Regeneron Pharmaceuticals have announced that the European Commission (EC) has granted marketing authorisation of Kevzara in combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adults Read more

News

Sanofi and Regeneron Pharmaceuticals have announced the FDA’s approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) Read more

News

Sanofi and Regeneron Pharmaceuticals has announced that the FDA has accepted the resubmission of the biologics licence application for Kevzara (sarilumab) as a Class I response with a two-month review timeline. Read more

News

Sanofi and Regeneron have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the marketing authorisation of Kevzara (sarilumab). Read more

News